$RLFTF Today - Scientific and Medical Aspects of D
Post# of 653
(Total Views: 289)
Posted On: 08/16/2020 9:35:58 AM
$RLFTF Today - Scientific and Medical Aspects of Dealing With COVID-19
78 Minutes
Join Meeting
This Sunday, August 16th, 2 pm ET; princeton78.com
(please note start time is different than the last 2 sessions)
What are the medical, pharmaceutical, and scientific communities doing to understand how COVID-19 operates, and to provide new treatments and vaccines that can lead us out of this pandemic?
Please join Stephen Chanock, Director of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute (NCI), who currently leads a project to learn who is more at risk for COVID-19 and what kinds of outcomes certain people are likely to incur, and Jonathan Javitt, CEO of U.S.-Israel-based NeuroRX, which just started Phase 2/3 clinical trials of RLF-100, a drug for the treatment of respiratory distress in COVID-19 patients.
This session will be moderated by Yale School of Medicine communicator and former CBS News producer and reporter Rob Forman. Log in at princeton78.com starting at 1:45 pm ET to catch up with classmates before we start the session!
As before, each session will run 78 minutes, and be a panel followed by a general discussion/Q&A. And all you need to do is login at the class website princeton78.com via Zoom – they’re free!
And we welcome your suggestions for topics. What would you would like to hear about, and which Classmates you would like to hear it from?
We look forward to you joining us.
https://princeton78.com/posts/feed.asp
78 Minutes
Join Meeting
This Sunday, August 16th, 2 pm ET; princeton78.com
(please note start time is different than the last 2 sessions)
What are the medical, pharmaceutical, and scientific communities doing to understand how COVID-19 operates, and to provide new treatments and vaccines that can lead us out of this pandemic?
Please join Stephen Chanock, Director of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute (NCI), who currently leads a project to learn who is more at risk for COVID-19 and what kinds of outcomes certain people are likely to incur, and Jonathan Javitt, CEO of U.S.-Israel-based NeuroRX, which just started Phase 2/3 clinical trials of RLF-100, a drug for the treatment of respiratory distress in COVID-19 patients.
This session will be moderated by Yale School of Medicine communicator and former CBS News producer and reporter Rob Forman. Log in at princeton78.com starting at 1:45 pm ET to catch up with classmates before we start the session!
As before, each session will run 78 minutes, and be a panel followed by a general discussion/Q&A. And all you need to do is login at the class website princeton78.com via Zoom – they’re free!
And we welcome your suggestions for topics. What would you would like to hear about, and which Classmates you would like to hear it from?
We look forward to you joining us.
https://princeton78.com/posts/feed.asp
(0)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
Scroll down for more posts ▼